Moleculin Biotech is a pharmaceutical company focused on the development of anti-cancer drug candidates. Its lead product candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company is also engaged in the preclinical development of additional drug candidates, including additional immune and transcription modulators as well as metabolism and glycosylation inhibitors.